Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Drug response prediction in high-risk multiple myeloma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

APA

CBE

MLA

Vancouver

Author

Bibtex

@article{80e8699087f143a0904f780b6455db3c,
title = "Drug response prediction in high-risk multiple myeloma",
abstract = "A Drug Response Prediction (DRP) score was developed based on gene expression profiling (GEP) from cell lines and tumor samples. Twenty percent of high-risk patients by GEP70 treated in Total Therapy 2 and 3A have a progression-free survival (PFS) of more than 10years. We used available GEP data from high-risk patients by GEP70 at diagnosis from Total Therapy 2 and 3A to predict the response by the DRP score of drugs used in the treatment of myeloma patients. The DRP score stratified patients further. High-risk myeloma with a predicted sensitivity to melphalan by the DRP score had a prolonged PFS, HR=2.4 (1.2-4.9, P=0.014) and those with predicted sensitivity to bortezomib had a HR 5.7 (1.2-27, P=0.027). In case of predicted sensitivity to bortezomib, a better response to treatment was found (P=0.022). This method may provide us with a tool for identifying candidates for effective personalized medicine and spare potential non-responders from suffering toxicity.",
keywords = "Antineoplastic Agents, Bortezomib, Disease-Free Survival, Gene Expression Profiling, Humans, Multiple Myeloma, Transcriptome, Clinical Trial, Phase III, Journal Article",
author = "Vangsted, {A J} and S Helm-Petersen and Cowland, {J B} and Jensen, {P B} and P Gimsing and B Barlogie and S Knudsen",
note = "Copyright {\circledC} 2017 Elsevier B.V. All rights reserved.",
year = "2018",
month = "2",
day = "20",
doi = "10.1016/j.gene.2017.10.071",
language = "English",
volume = "644",
pages = "80--86",
journal = "Gene",
issn = "0378-1119",
publisher = "Elsevier BV",

}

RIS

TY - JOUR

T1 - Drug response prediction in high-risk multiple myeloma

AU - Vangsted, A J

AU - Helm-Petersen, S

AU - Cowland, J B

AU - Jensen, P B

AU - Gimsing, P

AU - Barlogie, B

AU - Knudsen, S

N1 - Copyright © 2017 Elsevier B.V. All rights reserved.

PY - 2018/2/20

Y1 - 2018/2/20

N2 - A Drug Response Prediction (DRP) score was developed based on gene expression profiling (GEP) from cell lines and tumor samples. Twenty percent of high-risk patients by GEP70 treated in Total Therapy 2 and 3A have a progression-free survival (PFS) of more than 10years. We used available GEP data from high-risk patients by GEP70 at diagnosis from Total Therapy 2 and 3A to predict the response by the DRP score of drugs used in the treatment of myeloma patients. The DRP score stratified patients further. High-risk myeloma with a predicted sensitivity to melphalan by the DRP score had a prolonged PFS, HR=2.4 (1.2-4.9, P=0.014) and those with predicted sensitivity to bortezomib had a HR 5.7 (1.2-27, P=0.027). In case of predicted sensitivity to bortezomib, a better response to treatment was found (P=0.022). This method may provide us with a tool for identifying candidates for effective personalized medicine and spare potential non-responders from suffering toxicity.

AB - A Drug Response Prediction (DRP) score was developed based on gene expression profiling (GEP) from cell lines and tumor samples. Twenty percent of high-risk patients by GEP70 treated in Total Therapy 2 and 3A have a progression-free survival (PFS) of more than 10years. We used available GEP data from high-risk patients by GEP70 at diagnosis from Total Therapy 2 and 3A to predict the response by the DRP score of drugs used in the treatment of myeloma patients. The DRP score stratified patients further. High-risk myeloma with a predicted sensitivity to melphalan by the DRP score had a prolonged PFS, HR=2.4 (1.2-4.9, P=0.014) and those with predicted sensitivity to bortezomib had a HR 5.7 (1.2-27, P=0.027). In case of predicted sensitivity to bortezomib, a better response to treatment was found (P=0.022). This method may provide us with a tool for identifying candidates for effective personalized medicine and spare potential non-responders from suffering toxicity.

KW - Antineoplastic Agents

KW - Bortezomib

KW - Disease-Free Survival

KW - Gene Expression Profiling

KW - Humans

KW - Multiple Myeloma

KW - Transcriptome

KW - Clinical Trial, Phase III

KW - Journal Article

U2 - 10.1016/j.gene.2017.10.071

DO - 10.1016/j.gene.2017.10.071

M3 - Journal article

VL - 644

SP - 80

EP - 86

JO - Gene

JF - Gene

SN - 0378-1119

ER -

ID: 52710787